

Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)

Meeting – September 13, 2017 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. July 12, 2017 DUR Minutes – Vote
- B. July 12, 2017 DUR Recommendations Memorandum
- C. Correspondence

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Medicaid Opioid Utilization Comparison – See Appendix B

- A. Medication Coverage Activity for July 2017
- B. Pharmacy Help Desk Activity for July 2017
- C. Medication Coverage Activity for August 2017
- D. Pharmacy Help Desk Activity for August 2017
- E. Medicaid Opioid Utilization Comparison

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Radicava™ (Edaravone) – See Appendix C

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Eucrisa™ (Crisaborole 2% Ointment), Dupixent® (Dupilumab Injection), & Prudoxin™ and Zonalon® (Doxepin 5% Cream) – See Appendix D

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Vimizim® (Elosulfase Alfa) – See Appendix E

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Rayaldee® (Calcifediol), Parsabiv™ (Etelcalcetide), Zemplar® (Paricalcitol Capsules), and Hectorol® (Doxercalciferol Capsules) – See Appendix F

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Marplan® (Isocarboxazid) and Desyrel® (Trazodone 300mg Tablets) – See Appendix G

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nichols, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Choline Fenofibrate Delayed-Release (Trilipix®) 135mg Capsules and Fenofibrate Micronized (Lofibra®) 200mg Capsules – See Appendix H

- A. Cost Comparison
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Arymo™ ER (Morphine Sulfate Extended-Release), Troxyca® ER (Oxycodone/Naltrexone Extended-Release), Vantrela™ ER (Hydrocodone Extended-Release), Oxaydo® (Oxycodone), and RoxyBond™ (Oxycodone) – See Appendix I

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

12. Action Item – Vote to Prior Authorize Brineura™ (Cerliponase Alfa) – See Appendix J

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

13. Annual Review of Breast Cancer Medications and 30-Day Notice to Prior Authorize Kisqali® (Ribociclib), Kisqali® Femara® Co-Pack (Ribociclib/Letrozole), and Nerlynx™ (Neratinib) – See Appendix K

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Breast Cancer Medications
- D. Prior Authorization of Breast Cancer Medications
- E. Market News and Updates
- F. Product Summaries
- G. Recommendations
- H. Utilization Details of Breast Cancer Medications

Items to be presented by Dr. Ratterman, Dr. Muchmore, Chairman:

14. Annual Review of Factor Replacement Products and 30-Day Notice to Prior Authorize Afstyla® [Antihemophilic Factor (Recombinant), Single Chain] and Rebinyn® [Coagulation Factor IX (Recombinant), GlycoPEGylated] – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Factor Replacement Products
- C. Prior Authorization of Factor Replacement Products
- D. Mark News and Updates
- E. Afstyla® [Antihemophilic Factor (Recombinant), Single Chain] Product Summary
- F. Rebinyn® [Coagulation Factor IX (Recombinant), GlycoPEGylated] Product Summary
- G. Recommendations
- H. Utilization Details of Factor Replacement Products

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

15. Action Item – Annual Review of Growth Hormone – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of Growth Hormone
- C. Prior Authorization of Growth Hormone
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Growth Hormone

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

16. Annual Review of Synagis® (Palivizumab) – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Synagis® (Palivizumab)
- C. Prior Authorization of Synagis® (Palivizumab)
- D. Season Comparison
- E. Market News and Updates
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

17. 30-Day Notice to Prior Authorize Endari™ (L-Glutamine) – See Appendix O

- A. Introduction
- B. Market News and Updates
- C. Endari™ (L-Glutamine) Product Summary
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Nichols, Dr. Muchmore, Chairman:

18. Action Item – Annual Review of Insomnia Medications – See Appendix P

- A. Current Prior Authorization Criteria
- B. Utilization of Insomnia Medications
- C. Prior Authorization of Insomnia Medications
- D. Market News and Updates
- E. Non-24-Hour Sleep-Wake Rhythm Disorder
- F. College of Pharmacy Recommendations
- G. Utilization Details of Insomnia Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

19. 30-Day Notice to Prior Authorize Fabrazyme® (Agalsidase Beta) – See Appendix Q

- A. Introduction
- B. Utilization of Fabrazyme® (Agalsidase Beta)
- C. Market News and Updates
- D. Fabrazyme® (Agalsidase Beta) Product Summary
- E. Coverage Information
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

20. Annual Review of Antihyperlipidemics and 30-Day Notice to Prior Authorize Zypitamag™ (Pitavastatin Magnesium) and Nikita™ (Pitavastatin Sodium) – See Appendix R

- A. Current Prior Authorization Criteria
- B. Utilization of Antihyperlipidemics
- C. Prior Authorization of Antihyperlipidemics
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Antihyperlipidemics

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

21. Annual Review of Alzheimer’s Disease Medications and 30-Day Notice to Prior Authorize Namenda XR® (Memantine Extended-Release Capsules) – See Appendix S

- A. Current Prior Authorization Criteria
- B. Utilization of Alzheimer’s Disease Medications
- C. Prior Authorization of Alzheimer’s Disease Medications
- D. Market News and Updates
- E. Namenda XR® (Memantine Extended-Release Capsules) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Alzheimer’s Disease Medications

Non-Presentation; Questions Only:

22. Annual Review of Anticoagulants and Platelet Aggregation Inhibitors – See Appendix T

- A. Current Prior Authorization Criteria
- B. Utilization of Anticoagulants and Platelet Aggregation Inhibitors
- C. Prior Authorization of Anticoagulants and Platelet Aggregation Inhibitors
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Anticoagulants
- G. Utilization Details of Platelet Aggregation Inhibitors

Non-Presentation; Questions Only:

23. Industry News and Updates – See Appendix U

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

24. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix V

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

25. Future Business* (Upcoming Product and Class Reviews)

October meeting rescheduled to October 4, 2017 at 4PM

- A. Topical Corticosteroid Medications
- B. Targeted Immunomodulator Agents
- C. Allergy Immunotherapies
- D. Skin Cancer Medications
- E. Malignant Hematology Medications
- F. Constipation and Diarrhea Medications
- G. Bladder Control Medications
- H. Hereditary Angioedema Medications
- I. Anti-Ulcer Medications
- J. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

**Future business subject to change.*

26. Adjournment